UNSPSC 51332813: Oxaflumazine

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0ME957NZRY. European Medicines Agency schedules Oxaflumazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09487MIG. Oxaflumazine generally arises in the molecular formula C26H32F3N3O2S.

UNSPSC 51332813 Oxaflumazine (Commodity) does not align with the state and local procurement activity currently tagged to this code. The single recent opportunity in the source—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and drug deactivation systems for community health initiatives, not oxaflumazine, a pharmaceutical compound with a different chemical and therapeutic profile. The mismatch suggests either a classification error in the county's tagging or a data anomaly; oxaflumazine itself does not appear in the available recent opportunity record.

Seminole County, Florida, posted the naloxone procurement as an IFB on June 30, 2026, with a response deadline of July 26, 2023 (a retroactive date that indicates a historical or duplicated record). The county seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida. Vendors must include shipping and delivery costs, provide unit pricing, maintain specified insurance coverage, comply with E-Verify requirements, and meet federal compliance obligations tied to potential FEMA funding. The contract term runs for two years with a one-year renewal option and includes a three-month probationary termination clause. No set-aside designations are specified. Without additional recent opportunities under this code from other jurisdictions or states, the current activity record provides no meaningful signal for business development purposes under the Commodity 51332813 classification.